Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PST-611 in Subjects With Dry Age-related Macular Degeneration
NCT07024732Phase 1Completed
- Sponsor
- Eyevensys
- Start
- Jun 2025
- Primary completion
- Apr 2026
- Modality
- Gene Editing, Acoustic/Optical: Sonoporation, laser photoporation, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of EYS611 in age-related macular degeneration (AMD), sponsored by Eyevensys. Primary endpoint: Safety and Tolerability. Started Jun 2025; status: completed.
02
Drugs
EYS611
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT07024732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07024732.